Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects
Authors:
M. Krásenská
Authors‘ workplace:
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Published in:
Klin Onkol 2016; 29(Supplementum 3): 39-49
Category:
Review
doi:
https://doi.org/10.14735/amko20163S39
Overview
Background:
The third generation aromatase inhibitors (anastrozole, letrozole, exemestane) have become standard endocrine treatment for postmenopausal estrogen receptor – positive breast cancers in all settings (neoadjuvant, adjuvant, metastatic breast cancer), based on superiority to tamoxifen. Aromatase inhibitors interfere with the conversion of androgens into estrogens by blocking the enzyme aromatase resulting in low estradiol levels. Aromatase inhibitors are contraindicated in women with functional ovaries. Many premenopausal women develop amenorrhea after adjuvant chemoterapy. Aromatase inhibitors may promote recovery of ovarian function which could lead to therapeutic failure or even to unexpected pregnancy. Currently available measures to determine the menopausal status are conflicting.
Aim:
This paper focuses primarily on adverse effects of aromatase inhibitors which can lead to non-compliance or to discontinuation of treatment.
Results:
Many side effects of aromatase inhibitors are related to estrogen deprivation. On the other hand as aromatase inhibitors lack estrogenic activity, they are not associated with serious adverse events typical for tamoxifen, such as endometrial cancer and thromboembolic disease. Aromatase inhibitors therapy is often associated with vasomotor symptoms (hot flashes), vaginal dryness, dyspareunia, bone loss, arthralgias and myalgias (musculoskeletal symptoms). Management of these side effects can lead to improved adherence and persistence with therapy.
Key words:
breast cancer – menopause – aromatase inhibitors – ovarian function recovery – adverse effects
This work was supported by Czech Ministry of Health – RVO (MOÚ, 00209805).
The author declares she has no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted:
10. 7. 2016
Accepted:
3. 8. 2016
Sources
1. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12 (11): 1527–1532.
2. Wang W, Liu C, Zhou W et al. Network Meta-analysis of the effectiveness of neoadjuvant endocrine therapy for postmenopausal, HR-positive breast cancer. Sci Rep 2016; 6: 25615. doi: 10.1038/srep25615.
3. Henry NL, Somerfield MR, Abramson VG et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. J Clin Oncol 2016; 34 (19): 2303–2311. doi: 10.1200/JCO.2015.65.8609.
4. Coates AS, Winer EP, Goldhirsch A et al. Tailoring therapies – improving management of early breast cancer: St Gallen International Expert Consensus on the Primar Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26 (8): 1533–1546. doi: 10.1093/annonc/mdv221.
5. Senkus E, Kyriakides S, Ohno S et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl 5): v8–v30. doi: 10.1093/annonc/mdv298.
6. Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28 (3): 509–518. doi: 10.1200/JCO.2009.23.1274.
7. Goss P, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor – positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97 (17): 1262–1271.
8. Rugo HS, Rumble RB, Macrade E et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; JCO671487. doi: 10.1200/JCO.2016.67. 1487.
9. Gibson L, Lawrence D, Dawson C et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009; 4: CD003370. doi: 10.1002/14651858.CD003370.pub3.
10. Di Leo A, Jerusalem G, Petruzelka L et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28 (30): 4594–4600. doi: 10.1200/JCO.2010.28.8415.
11. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Eng J Med 2012; 366 (6): 520–529. doi: 10.1056/NEJMoa1109653.
12. Lønning PE, Eikesdal HP. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer 2013; 20 (4): 183–201. doi: 10.1530/ERC-13-0099.
13. Kwan ML, Chen WY, Kroenke CH et al. Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 2011; 132 (2): 729–739. doi: 10.1007/s10549-011-1914-3.
14. Sestak I, Distler W, Forbes JF et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010; 28 (21): 3411–3415. doi: 10.1200/JCO.2009.27.2021.
15. Folkerd EJ, Dixon JM, Renshaw L et al. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 2012; 30 (24): 2977–2980. doi: 10.1200/JCO. 2012.42.0273.
16. Soler JT, Folsom AR, Kaye SA et al. Associations of abdominal adipozity, fasting insulin, sex hormone binding globulin, and estrone with lipids and lipoproteins in post-menopausal women. Aterosclerosis 1989; 79 (1): 21–27.
17. Casper RF, Mitwally FM. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 2006; 91 (3): 760–771.
18. Smith IE, Dowsett M, Yap YS et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006; 24 (16): 2444–2447.
19. Dowsett M, Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res 2005; 7 (1): 1–4.
20. Referenční hodnoty laboratorních vyšetření OLM MOÚ. [online]. Dostupné z: www.mou.cz.
21. Folkerd EJ, Lonning PE, Dowsett M. Interpreting plasma estrogen levels in breast cancer: caution needed. J Clin Oncol 2014; 32 (14): 1396–1400. doi: 10.1200/JCO.2013.53.9411.
22. Burger HG, Dudley EC, Hopper JL et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999; 84 (11): 4025–4030.
23. Rossi E, Morabito A, Di Rella F et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 2009; 27 (19): 3192–3197. doi: 10.1200/JCO.2008.18.6213.
24. Han HS, Ro J, Lee KS et al. Analysis of chemotherapy-induced amenorhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 2009; 115 (2): 335–342. doi: 10.1007/s10549-008-0071-9.
25. Sherman BM, Chapler FK, Crickard K et al. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 1979; 64: 398–404.
26. Krekow LK, Hellrstedt BA, Collea RP et al. Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole. J Clin Oncol 2016; 34 (14): 1594–1600. doi: 10.1200/JCO.2015.62.2985.
27. Guerrero A, Gavilá J, Folkerd E et al. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Ann Oncol 2013; 24 (3): 674–679. doi: 10.1093/annonc/mds464.
28. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14 (5): 1718–1729.
29. Bellet M, Gray KP, Francis PA et al. Twelve-month estrogen levels in premenopausal women with hormone receptor – positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. J Clin Oncol 2016; 34 (14): 1584–1593. doi: 10.1200/JCO.2015.61.2259.
30. Fait T. Klimakterická medicína. Maxdorf 2006: 15–17.
31. Morrow PK, Mattair DN, Hortobagyi GN. Hot flashes: a review of pathophysiology and treatment modalities. Oncologist 2011; 16 (11): 1658–1664. doi: 10.1634/theoncologist.2011-0174.
32. Loprinzi CL, Zahasky KM, Sloan JA et al. Tamoxifen-induced hot flashes. Clin Breast Cancer 2000; 1 (1): 52–56.
33. Howell A, Cuzick J, Baum M et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365 (9453): 60–62.
34. Thurlimann B, Keshavian A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Eng J Med 2005; 353 (26): 2747–2757.
35. Coombes RC, Kilbum LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2–3 years tamoxifen treatment (Intergroup Exemes- tane Study): a randomised controlled trial. Lancet 2007; 369 (9561): 559–570.
36. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366 (9484): 455–462.
37. Mar Fan HG, Houédé-Tchen N, Chemerynsky I et al. Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study. Ann Oncol 2010; 21 (5): 983–987. doi: 10.1093/annonc/mdp394.
38. Barton DL, LaVasseur BI, Sloan JA et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG Trial N05C9. J Clin Oncol 2010; 28 (20): 3278–3283. doi: 10.1200/JCO.2009.26.6379.
39. Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356 (9247): 2059–2063.
40. Guttuso T Jr, Kurlan R, McDermott MP et al. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003; 101 (2): 337–345.
41. Bordeleau L, Pritchard KI, Loprinzi CL et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010; 28 (35): 5147–5152. doi: 10.1200/JCO.2010.29.9230.
42. Laufer LR, Erlik Y, Meldrum DR et al. Effect of clonidine on hot flashes in postmenopausal women. Obst Gynecol 1982; 60 (5): 583–586.
43. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003; 6 (1): 45–52.
44. Kendall A, Dowsett M, Folkerd E et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17 (4): 584–587.
45. Wills S, Ravipati A, Venuturumilli P et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Practice 2012; 8 (3): 144–148. doi: 10.1200/JOP.2011.000352.
46. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency – a pharmacokinetic and pharmacodynamic study. Maturitas 1992; 15 (2): 121–127.
47. Key T, Appleby P, Barnes I et al. Endogenous hormones and breast cancer collaborative group. endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94 (8): 606–616.
48. Lonning PE, Haynes B, Straume AH et al. Exploring breast cancer estrogen disposition: the basis for endocrine manipulation. Clin Cancer Res 2011; 17 (15): 4948–4958. doi: 10.1158/1078-0432.CCR-11-0043.
49. Nachtigall LE. Comparative study: replens versus local oestrogen in menopausal women. Fertil Steril 1994; 61 (1): 178–180.
50. Loprinzi CL, Abu-Ghazaleh S, Sloan J et al. Phase III randomized double blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997; 15 (3): 969–973.
51. Van der Laak JA, de Bie LM, de Leeuw H et al. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomophology versus computerised cytometry. J Clin Pathol 2002; 55 (6): 446–451.
52. Informace o přípravku Regelle Intimed. [online]. Dostupné z: http: //www.dmdrogeriemarkt.cz/cz_homepage/nove/nove_produkty/771700/regelle.html; http: //www.intimedcare.cz/.
53. Donders G, Neven P, Moegele M et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 2014; 145 (2): 371–379. doi: 10.1007/s10549-014-2930-x.
54. Goetsch MF, Lim JY, Caughey AB. A Practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol 2015; 33 (30): 3394–3400. doi: 10.1200/JCO.2014.60.7366.
55. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007; 18 (Suppl 8): viii26–viii35.
56. McCloskey E, Eastell R, Lakner G et al. Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Canbcer Res Treat 2005; 94 (Suppl 1): abstr. 2052.
57. Štěpán J. Osteoporóza a zlomeniny ve vyšším věku. [online]. Dostupné z: http: //www.osteo-liga.cz/index.php/osteoporoza.
58. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997; 103 (2A): 12S–17S.
59. Roberts SE, Goldacre MJ. Time trends and demography of mortality after fractured neck of femur in an English population, 1968–98: database study. BMJ 2003; 327 (7418): 771–775.
60. Colón-Emeric C, Kuchibhatla M, Pieper C. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int 2003; 14 (11): 879–883.
61. Coleman RE. Effect of anastrozole on bone mineral density: 5-year results from the ’Arimidex’, tamoxifen, alone or in combination (ATAC) trial. J Clin Oncol 2006; 24 (Suppl): 5s; abstr. 511.
62. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24: 3229–3635.
63. Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breayst cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007; 8 (2): 119–127.
64. Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19 (8): 1407–1416. doi: 10.1093/annonc/mdn164.
65. Jackson RD, LaCroix AZ, Gass M et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354 (7): 669–683.
66. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid effectively prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25 (7): 820–828.
67. Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25 (7): 829–836.
68. Bundred N, Cambell I, Coleman R et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZOFAST study). Nice, France: Presented at 5th European Breast Cancer Conference, 21–25 March 2006; abstr. 12.
69. Schenk N, Lombart A, Frassoladti A et al. The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (LET). Barcelona, Spain: presented at ECCO 14: the European Cancer Conference, 23–27 September 2007; abstr. 2008.
70. De Boer R. Zoledronic acid in the prevention of aromatase inhibitor-associated bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST Trial). Breast Cancer Res Treat 2007; 106 (Suppl 1): S36; abstr. 501.
71. Coleman R, Gnant M, Paterson A et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials. Program and abstracts of the 2013 San Antonio Breast Cancer Symposium; December 10–14, 2013; San Antonio, Texas: abstr. S4–07.
72. Crew K, Greenlee H, Capodice J et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early stage breast cancer. J Clin Oncol 2007; 25 (25): 3877–3883.
73. Henry N, Giles J, Ang D et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008; 111 (2): 365–372.
74. Cuzick J, Sestak I, Cella D. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC Trial. Lancet Oncol 2008; 9 (12): 1143–1148. doi: 10.1016/S1470-2045 (08) 70259-6.
75. Hadji P, Kieback D, Tams J et al. Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. Ann Oncol 2012; 23 (10): 2566–2572.
76. Huober J, Cole B, Wu J et al. Symptoms of endocrine treatment and outcome: a retrospective analysis of the monotherapy arms of the BIG 1-98 trial. Paper presented at: 2011 ASCO Annual Meeting; June 2011, Chicago, IL.
77. Cutolo M, Villagio B, Seriolo B et al. Synovial fluid estrogens in rheumatoid arthritis. Autoimmun Rev 2003; 3 (3): 193–198.
78. Moraless L, Pans S, Paridaens R et al. Debilitanting musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 2007; 104 (1): 87–91.
79. Irwin ML, Cartmel B, Gross CP et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 2015; 33 (10): 1104–1111. doi: 10.1200/JCO.2014.57.1547.
80. Briot K,Tubiana-Hulin M, Bastit L et al. Effect of a switch of aromatase inhibitors on musculoskeletal symptioms in postmenopausal women with hormone-receptor-positive breast cancer: the ATTOL study. Breast Cancer Res Treat 2010; 120 (1): 127–134.
81. Khan Q, Reddy P, Kimler B et al. Effect of vitamin D supplentation on serum 25 hydroxy vitamin D levels, joint pains, and fatique in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119 (1): 111–118. doi: 10.1007/s10549-009-0495-x.
82. Crew KD, Capodice JL, Greenlee H et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 2010; 28 (7): 1154–1160. doi: 10.1200/JCO.2009.23.4708.
83. Greenlee H, Crew KD, Shao T et al. Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Supp Care Cancer 2013; 21 (4): 1077–1087. doi: 10.1007/s00520-012-1628-z.
84. Kubo M, Onishi H, Kuroki S et al. Short term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res 2012; 32 (6): 2331–2336.
85. Henry N, Banerjee M, Wicha M et al. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptomas. Cancer 2011; 117 (24): 5469–5475. doi: 10.1002/cncr.26230.
86. Andreetta C, Smith I. Adjuvant endocrine therapy for early breast cancer. Cancer Lett 2007; 251 (1): 17–27.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2016 Issue Supplementum 3
Most read in this issue
- Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects
- Breast Cancer – Specifics of Gynecological Care and Counseling
- Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications
- Pregnancy after Treatment of Breast Cancer